Another win for brain centric obesity treatment approaches. Adding cagrilintide (an amylin analog) to semaglutide (a GLP 1 analog) enhances weight loss. 17.1% weight loss over 20 wk at highest dose, with weight still Cagrilintide: What It Is and How It's Being Studied for Weight Loss Good looking results for Novo Nordisk's combo of GLP1ra semaglutide (known as #ozempic for #diabetes & #wegovy for obesity) + Cagrilintide (amylin agonist) to achieve #weightloss in obesity and obesity with type Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 24 mg for weight management: a randomised, controlled, phase 1b trial The Lancet NVO Stock Rises on Upbeat Phase III Data for Cagrilintide in Obesity Supplementary appendix